Journal articles, eBooks, news, events, and other information about biological and medicinal chemistry from @ACSPublications, a division of @AmerChemSociety
Check out this Perspective in #JMedChem: gem-dimethylcarbinol can be considered as a tert-butyl bioisostere. Add C(CH3)2OH to your list of favorite bioisosteres!
go.acs.org/ePz
How can scaffold hybridization overcome ADME liabilities? Explore the discovery of INCB187175, an orally bioavailable MRGPRX2 antagonist optimized through systematic SAR. #ACSMedChemLettgo.acs.org/ePh
We’re proud to announce that we are now accepting nominations for the Biological and Medicinal Chemistry Fall 2027 Lectureships & Awards.
🗓️ Deadline: December 2026 (self-nominations welcome
🔗 Learn more and submit your nomination: go.acs.org/eOl
Deadline approaching 🚨
Are you using AI in your biomaterials research? 🤔
Submit your manuscript by Nov 30 🗓️ to be included in this upcoming Special Issue from #ACSAppliedBioMaterials and #ACSPT
More info ➡️ go.acs.org/eNl
ALT ACS Applied Bio Materials and ACS Pharmacology & Translational Science Call for Papers: Artificial Intelligence in the Development of Biomaterials
Researchers report comprehensive structure–activity relationship studies, supported by structural, computational, and pharmacological data, that led to the discovery of Cpd40, a novel brain-penetrant colchicine-binding site inhibitor. #JMedChemgo.acs.org/eMG
SMILES-based deep learning designs chemically modified ultrashort antimicrobial peptides, expanding peptide chemical space for next-generation antibiotics. #JMedChemgo.acs.org/eMj
Make sure your work is included in the next Special Issue from #BioconjugateChemistry!
Submit your manuscript to the Targeted Protein and Nucleic Acid Degradation call for papers 📑
Learn more ➡️ go.acs.org/eM2
ALT Bioconjugate Chemistry Call for Papers: Targeted Protein and Nucleic Acid Degradation
Submit your manuscript
ACS Publications
From 2D to 3D: Ruthenium complexes with pyrithione and P-donor ligands retain potent anticancer activity in ovarian cancer spheroids, highlighting their promise in physiologically relevant tumor models. #JMedChemgo.acs.org/eKR
.@Johannes_Karges and co-workers introduce the first vanadium(II) photosensitizer excitable at 630 nm, demonstrating the potential of earth-abundant metals for next-generation photodynamic therapy. #JMedChemgo.acs.org/eJY
Call for Papers: Carbohydrates
Final Reminder: Don't miss your chance to contribute your research to this Special Issue on carbohydrates.
Submit by September 30:
go.acs.org/eH9
Call for Papers: Carbohydrates
Don't miss the opportunity to share your work in this Special Issue on carbohydrates.
Participating ACS journals invite high-quality submissions on cutting-edge carbohydrate research.
Submit by September 30: go.acs.org/eH7
Vipergen paper: A 96-well plate workflow for DEL building block conjugation – reducing hands-on time without compromising quality. Broadly applicable – covers templated and split-and-mix formats. #BioconjChemgo.acs.org/eGF
From in silico to zebrafish: this integrated ensemble docking and in vivo phenotypic screening platform improves drug-induced liver injury prediction of molecules while reducing the false positives. #ACSMedChemLettgo.acs.org/eGm
Researchers publishing in the Journal of Medicinal Chemistry have developed a novel approach (pkCSM) which uses graph-based signatures to develop predictive models of central ADMET properties for drug development.
Explore the article: go.acs.org/eFW
Using genetic code expansion, Addo et al. engineered YTH reader proteins with noncanonical tryptophan derivatives to improve m6A-RNA recognition, likely through tuning CH–π interaction between m6A and YTH. #ACSChemBiogo.acs.org/eEP
Call for Papers: Methods and Protocols in Biochemistry
Biochemistry announces Methods/Protocols as a manuscript type, replacing From the Bench articles, capturing new and improved techniques that help to drive the field forward.
Submit your paper: go.acs.org/eEz
New research in #JMedChem: DT-9081, a potent oral EP4R antagonist to counter PGE2-driven immunosuppression and synergize with immunotherapy/chemotherapy to improve antitumor responses.
go.acs.org/eEh
Why do some PROTACs show incomplete target degradation? In this @ACSPublications article, the authors reveal that protein age matters: older proteins are degraded more efficiently than newly synthesized ones. #ACSChemBiogo.acs.org/eDa